Table 2:

Treatment characteristics and outcomes

ParameterNo.
No. of FREDs per aneurysm
    1 FRED80 (95.2%)
    2 FREDs3 (3.6%)
    4 FREDs1 (1.2%)
Adjunctive coiling required14 (16.7%)
Platelet function testing80 (95.2%)
Antiplatelet regimen changed after testing2 (2.4%)
Postprocedural antiplatelet regimen
    ASA + clopidogrel62 (73.8%)
    Tirofiban loading followed by ASA + clopidogrel11 (13.1%)
    ASA + ticagrelor6 (7.1%)
    Prasugrel3 (3.6%)
    ASA + prasugrel1 (1.2%)
    ASA + tirofiban + ticagrelor1 (1.2%)
Thromboembolic infarction due to procedure11 (13.1%)
Symptomatic thromboembolic complication8 (9.5%)
Location of infarction
    Cerebellum7 (8.3%)
    Brain stem2 (2.4%)
    Posterior cerebral artery territory1 (1.2%)
    Thalamus1 (1.2%)
Hemorrhagic complications0 (0.0%)
Other complications3 (3.6%)
Parent artery occlusion2 (2.4%)
Time of radiographic follow-up (median) (range) (mo)a24 (0.03–72)
Occlusion status last imaging follow-upa
    Complete occlusion (100%)61 (78.2%)
    Near-complete occlusion (>90%)7 (9%)
    Incomplete occlusion (<90%)10 (12.8%)
Imaging techniqueb
    MRA34 (50%)
    DSA31 (45.6%)
    Conebeam CT with IV contrast2 (2.9%)
    CTA1 (1.5%)
Retreatmentc6 (7.1%)
Time of functional outcome follow-up (median) (range) (mo)d27 (0.03–72)
Functional outcomee
    mRS 0–278 (94%)
    mRS 3–50
    mRS 65 (6%)

  • Note:—ASA indicates acetylsalicylic acid.

  • ↵a Data missing in 6 patients.

  • ↵b Data missing in 16 patients.

  • ↵c Data missing in 1 patient.

  • ↵d Data missing in 6 patients.

  • ↵e Data missing in 1 patient.